BlossomHill Therapeutics (NASDAQ:BLSM) Reaches New 12-Month High – Time to Buy?

BlossomHill Therapeutics, Inc. (NASDAQ:BLSM)’s share price reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $17.54 and last traded at $17.22, with a volume of 69520 shares. The stock had previously closed at $16.03.

Wall Street Analyst Weigh In

Separately, Wall Street Zen raised BlossomHill Therapeutics to a “hold” rating in a report on Saturday, August 15th.

BlossomHill Therapeutics Stock Up 10.2%

Insider Buying and Selling at BlossomHill Therapeutics

In other BlossomHill Therapeutics news, Director Carl L. Gordon purchased 625,000 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was purchased at an average cost of $16.00 per share, with a total value of $10,000,000.00. Following the acquisition, the director directly owned 2,714,279 shares of the company’s stock, valued at approximately $43,428,464. This trade represents a 29.91% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Bihua Chen acquired 312,500 shares of the business’s stock in a transaction on Monday, August 10th. The stock was acquired at an average price of $16.00 per share, with a total value of $5,000,000.00. Following the transaction, the director owned 3,614,034 shares in the company, valued at approximately $57,824,544. The trade was a 9.47% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased 1,573,900 shares of company stock worth $25,181,900 over the last 90 days.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.